Dr. Liang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
212 10th Ave. NE
New Prague, MN 56071Phone+1 952-758-4461Fax+1 952-758-5011
Education & Training
Hennepin HealthcareResidency, Family Medicine, 2000 - 2004
Beijing Medical UniversityClass of 1991
Certifications & Licensure
MN State Medical License 2003 - 2025- American Board of Family Medicine Family Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma Start of enrollment: 2010 Sep 01
- Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2011 Dec 01
Publications & Presentations
PubMed
- 36 citationsLead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biologica...Jun Liang, Birong Zhang, Sharada Labadie, Daniel F. Ortwine, Maia Vinogradova
Bioorganic & Medicinal Chemistry Letters. 2016-08-15 - 9 citationsUnexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha.Birong Zhang, James R. Kiefer, Robert A. Blake, Jae H. Chang, Steven J. Hartman
Bioorganic & Medicinal Chemistry Letters. 2019-04-01 - 68 citationsLead Optimization of a 4-Aminopyridine Benzamide Scaffold To Identify Potent, Selective, and Orally Bioavailable TYK2 InhibitorsJun Liang, Anne van Abbema, Mercedesz Balazs, Kathy Barrett, Leo Berezhkovsky
Journal of Medicinal Chemistry. 2013-05-29
Press Mentions
Radiotherapy Combined with Gefitinib for Patients with Locally Advanced Non-Small Cell Lung Cancer Who Are Unfit for Surgery or Concurrent Chemoradiotherapy: A Phase II Clinical TrialJune 20th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
